Paloma Partners’s Neurogene NGNE Stock Holding History

Paloma Partners’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,291	Closed	-$304K	–	2157
2017 Q4	$304K	Buy	+1,291	New	+$302K	﹤0.01%	1546

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Paloma Partners's NGNE Position: Q1 2018 in Review

Paloma Partners sold out of Neurogene (NGNE) in Q1 2018, closing a stake of 1,291 shares — an estimated $304K sold.

Paloma Partners first reported a position in NGNE in Q4 2017 and held it in 1 quarter. The position peaked at $304K in Q4 2017. 50 funds tracked by Wall St. Rank hold NGNE as of Q1 2018.

Paloma Partners reported no remaining Neurogene position as of Q1 2018 after selling out during the quarter.
Paloma Partners sold 1,291 Neurogene shares in Q1 2018, an estimated $304K.
Paloma Partners first reported a position in Neurogene in Q4 2017 and held it in 1 quarter.
Paloma Partners's Neurogene position peaked at $304K in Q4 2017.
50 funds tracked by Wall St. Rank held Neurogene as of Q1 2018.

Based on Paloma Partners's 13F filing for Q1 2018, filed 15 May 2018.